Compare · ALNY vs XCUR
ALNY vs XCUR
Side-by-side comparison of Alnylam Pharmaceuticals Inc. (ALNY) and Exicure Inc. (XCUR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALNY and XCUR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ALNY is the larger of the two at $19.26B, about 3269.7x XCUR ($5.9M).
- ALNY has been more active in the news (23 items in the past 4 weeks vs 8 for XCUR).
- ALNY has more recent analyst coverage (25 ratings vs 2 for XCUR).
- Company
- Alnylam Pharmaceuticals Inc.
- Exicure Inc.
- Price
- -
- -
- Market cap
- $19.26B
- $5.9M
- 1M return
- -36.77%
- -
- 1Y return
- -67.04%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2004
- News (4w)
- 23
- 8
- Recent ratings
- 25
- 2
Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Exicure Inc.
Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Latest ALNY
- Alnylam to Webcast Presentations at Upcoming December Investor Conferences
- Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years
- Chief Executive Officer Yvonne Greenstreet gifted 11,000 shares, decreasing direct ownership by 11% to 84,802 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Alnylam Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.
- Director Pyott David E I exercised 3,780 shares at a strike of $71.99, increasing direct ownership by 239% to 5,362 units (SEC Form 4)
- Director Sigal Charles Elliott bought $243,600 worth of shares (1,600 units at $152.25) (SEC Form 4)
- Director Schulman Amy W bought $299,526 worth of shares (1,910 units at $156.82), increasing direct ownership by 8% to 25,959 units (SEC Form 4)
- Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD
Latest XCUR
- SEC Form 10-Q filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure Announces Strategic Expansion into Parkinson’s Disease
- Exicure Announces Filing of Notification of Late Filing on Form 12b-25
- SEC Form DEF 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
- SEC Form PRE 14A filed by Exicure Inc.
- Exicure Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement